Summary & Overview
HCPCS Level II J7401: Mometasone Furoate Sinus Implant, 10 mcg
HCPCS Level II code J7401 represents a mometasone furoate sinus implant (10 micrograms) used to deliver localized corticosteroid therapy within the paranasal sinuses. The code identifies the implantable drug-device product and is relevant for facility and professional billing when the device is supplied and billed separately. Nationally, this code matters because it affects reimbursement pathways for office-based procedures, ambulatory surgical centers, and hospital outpatient departments treating chronic rhinosinusitis and related sinonasal conditions.
Key payers included in this review are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for implant use, typical sites of service, and the payer landscape addressed. The publication outlines benchmarks and fee-schedule considerations where available, highlights policy and coverage themes affecting access to implantable corticosteroid therapy, and summarizes common coding and billing considerations associated with J7401.
This summary is designed for revenue cycle leaders, coding and billing professionals, and clinical managers who need a national perspective on coding, coverage, and the operational implications for delivering sinonasal implant therapy.
Billing Code Overview
HCPCS Level II code J7401 represents a mometasone furoate sinus implant, 10 micrograms. This code denotes a drug device implant designed to deliver topical corticosteroid therapy directly to the sinonasal mucosa.
-
Service type: Drug implant administration
-
Typical site of service: Ambulatory surgical center or hospital outpatient setting
Clinical & Coding Specifications
Clinical Context
A 48-year-old patient with chronic rhinosinusitis with nasal polyposis who has persistent symptoms despite maximal medical therapy presents to an otolaryngology clinic. After nasal endoscopy confirms recurrent polyps and inflammation in the ethmoid and maxillary sinuses, the surgeon plans in-office or ambulatory operating room placement of a steroid-eluting sinus implant. The device delivered is a J7401 mometasone furoate sinus implant, 10 micrograms, placed into the ethmoid sinus recesses following limited endoscopic sinus dilation or targeted polypectomy. Typical workflow: pre-procedure assessment and informed consent; topical and/or local anesthesia; nasal endoscopy and any required minimal debridement or dilation; placement of the J7401 implant into the sinus cavity; post-placement endoscopic confirmation; brief recovery with discharge instructions and follow-up nasal endoscopy at 2–6 weeks to assess implant position and mucosal healing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the day of a procedure | Use when a distinct E/M visit is performed the same day as J7401 and meets documentation for a separate E/M |